Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.57 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.54 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.53 |
| ▸ | DHODH | Q02127 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.52 |
| ▸ | MYC | P01106 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22213632 | 0.94 | NPC1 (0.57) | NR1H4NPC1MAPTMRGPRX4LTC4S | |
| SCHEMBL22213507 | 0.89 | NPC1 (0.54) | NR1H4NPC1MAPTMRGPRX4DHODH | |
| SCHEMBL22213559 | 0.89 | KDM4E (0.57) | NR1H4NPC1MAPTMEN1KMT2A | |
| SCHEMBL27060795 | 0.88 | MAPT (0.53) | NR1H4NPC1MAPTMEN1KMT2A | |
| SCHEMBL22762665 | 0.86 | MEN1 (0.54) | NPC1MAPTMRGPRX4MEN1KMT2A | |
| SCHEMBL22213622 | 0.84 | KDM4E (0.57) | NR1H4NPC1MAPTMRGPRX4CASP3 | |
| SCHEMBL19554280 | 0.81 | IGF2BP2 (0.58) | NR1H4NPC1MAPTDHODHSLC16A3 | |
| SCHEMBL26358092 | 0.80 | NR1H4 (0.57) | NR1H4NPC1MAPTMEN1KMT2A | |
| SCHEMBL26358107 | 0.79 | MRGPRX4 (0.59) | NPC1MAPTMRGPRX4MEN1KMT2A | |
| SCHEMBL22762666 | 0.79 | MCL1 (0.60) | MAPTMRGPRX4MEN1KMT2ASLC16A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | HIROSHIMA UNIVERSITY (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | HIROSHIMA UNIVERSITY (JP) | 2024-01-25 | — | — | US | disclosed |
| US-20200383967-A1 | Novel Anthranilic Acid-Based Compound, and Pin1 Inhibitor, Therapeutic Agent for Inflammatory Diseases and Therapeutic Agent for Cancer That Use the Same | HIROSHIMA UNIVERSITY (JP) | 2020-12-10 | — | — | US | disclosed |
| EP-3680232-A1 | NOVEL ANTHRANILIC ACID-BASED COMPOUND, AND Pin1 INHIBITOR, THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES AND THERAPEUTIC AGENT FOR CANCER THAT USE THE SAME | Hiroshima University (JP) | 2020-07-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200383967-A1 | Novel Anthranilic Acid-Based Compound, and Pin1 Inhibitor, Therapeutic Agent for Inflammatory Diseases and Therapeutic Agent for Cancer That Use the Same | PIN1, NFKBIA, FKBP1A | NR1H4 507/4885NPC1 1045/4885MAPT 775/4885 |
| US-20240024266-A1 | Therapeutic Agent or Prophylactic Agent for COVID-19 | PIN1, ACE2, ACE | NR1H4 1665/4885NPC1 378/4885MAPT 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.